Drug Profile
Research programme: BUB1 kinase inhibitors - Bayer Pharma
Alternative Names: BAY-1816032; BAY-320; BAY-524Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Bayer
- Class Antineoplastics; Small molecules
- Mechanism of Action Bub1 spindle checkpoint protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Cancer in Germany (unspecified route) before September 2023
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in Germany
- 01 Apr 2017 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical trials in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)